Business Wire

ENCHROMA

15.7.2024 18:09:34 CEST | Business Wire | Press release

Share
Ravenna, City of Mosaics, UNESCO World Heritage Site, in Partnership with EnChroma and Fondazione Paolina Brugnatelli, Enables Color Blind Visitors to Rediscover the Colors of Mosaics

Opera di Religione della Diocesi di Ravenna, EnChroma, manufacturers of lenses for color blind users, Francesca Carlone, sustainable designer and founder of the project, Fondazione Paolina Brugnatelli and ITRIA announce today an initiative to enhance the experience of color blind visitors. Starting July 19, 2024, visitors with this vision condition will be able to borrow special glasses during their visit to live for the first time the experience of seeing light and bright color mosaics. The project, called ColoRaMi - color mosaics, will be introduced on July 19 at Basilica di Sant’Apollinare Nuovo as part of the Ravenna Mosaici FOR ALL program.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240714597763/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Basilica di San Vitale: Agnus Dei. Normal colour vision and colour blind view (Graphic: Business Wire)

In Italy, approximately 2.5 million people are color blind, a vision condition affecting a higher number of men (8%) vs. women (0.5%) and approximately 350 million people worldwide. Whereas people with normal color vision can see over one million shades of color, people with color vision deficit only see 10% of tones and shades. As a result, colors can appear dull or even indistinguishable. EnChroma lenses allow people with deuteranomaly and protanomaly to perceive a much wider range of colors.

Artistic and cultural heritage is enhanced also by improving its accessibility, safety, and inclusiveness. Thanks to ColoRaMi, Ravenna's Mosaics will be the world's first mosaics to be made accessible to color blind people. Starting Friday, July 19, EnChroma glasses will be distributed free of charge at the following locations: Basilica of Sant’Apollinare Nuovo, Mausoleum of Galla Placidia, Basilica of San Vitale, Neonian Baptistry, Archiepiscopal Museum, and Sant’Andrea Chapel, thus enabling visitors to see for the first time the mosaics in all their chromatic complexity.

The opening event on July 19, at 3:00 p.m. will host a “live reveal” event, in which a number of color blind participants will share the daily challenges of color blindness and the difference made by EnChroma lenses in their viewing experience of the multicolor nuances of the mosaics.

EVENT INFO:

When: Friday, July 19 at 3:00 p.m.
Where: Basilica of Sant’Apollinare Nuovo

What's a Live Reveal:

A "Live Reveal" is an opportunity for volunteers to test EnChroma glasses for the first time and share their experience. At the end of the day, the volunteers may keep their custom-made glasses.

About EnChroma glasses:

EnChroma glasses are the product of two NIH research grants and of clinical studies conducted at UC Berkeley and UC Davis, USA. In 2016, EnChroma glasses were awarded the Tibbetts Award by the U.S. Small Business Administration for their innovative technology-driven impact on individual experience. EnChroma glasses use special optical filters that help people with color vision deficiency (protanomaly and deuteranomaly) experience a wider range of colors, perceiving them as more accurate, brighter, and sharper. Please note: EnChroma glasses do not treat color blindness and work for 9 out of 10 color blind wearers.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240714597763/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release

Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release

First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release

Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release

“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye